Your browser is no longer supported. Please, upgrade your browser.
Settings
SGMO Sangamo Therapeutics, Inc. daily Stock Chart
SGMO [NASD]
Sangamo Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.81 Insider Own1.91% Shs Outstand82.43M Perf Week-2.83%
Market Cap1.13B Forward P/E- EPS next Y-0.80 Insider Trans-4.67% Shs Float82.01M Perf Month31.58%
Income-57.70M PEG- EPS next Q-0.19 Inst Own63.80% Short Float9.33% Perf Quarter47.85%
Sales23.40M P/S48.44 EPS this Y-74.10% Inst Trans26.48% Short Ratio4.96 Perf Half Y235.37%
Book/sh2.68 P/B5.13 EPS next Y2.40% ROA-30.70% Target Price14.60 Perf Year185.27%
Cash/sh3.03 P/C4.54 EPS next 5Y- ROE-38.50% 52W Range2.65 - 15.05 Perf YTD350.82%
Dividend- P/FCF96.05 EPS past 5Y-7.50% ROI-51.80% 52W High-8.64% Beta3.13
Dividend %- Quick Ratio6.10 Sales past 5Y13.40% Gross Margin- 52W Low418.87% ATR0.77
Employees131 Current Ratio6.10 Sales Q/Q124.30% Oper. Margin- RSI (14)59.46 Volatility4.28% 6.51%
OptionableYes Debt/Eq0.02 EPS Q/Q54.30% Profit Margin- Rel Volume1.08 Prev Close14.30
ShortableYes LT Debt/Eq0.02 EarningsAug 09 AMC Payout- Avg Volume1.54M Price13.75
Recom2.00 SMA203.64% SMA5024.94% SMA200107.93% Volume1,664,928 Change-3.85%
Jun-22-17Resumed Jefferies Buy $17
Nov-01-16Downgrade Wedbush Outperform → Neutral $30 → $4
Oct-19-16Downgrade Piper Jaffray Overweight → Neutral
Dec-04-15Initiated Wells Fargo Outperform
Oct-23-15Resumed Jefferies Buy
May-03-13Initiated BioLogic Equity Research Sell
Feb-23-11Reiterated JMP Securities Mkt Outperform $9 → $12
Jul-29-10Reiterated Wedbush Outperform $12 → $13
Oct-19-09Initiated Brean Murray Sell $4
Oct-07-09Reiterated Leerink Swann Outperform $9 → $11
Aug-25-09Reiterated JMP Securities Mkt Outperform $13 → $15
Apr-14-09Downgrade Cantor Fitzgerald Buy → Hold
Feb-23-09Reiterated Leerink Swann Outperform $6 → $9
Feb-05-09Upgrade Merriman Curhan Ford Neutral → Buy
Nov-20-08Reiterated Cantor Fitzgerald Buy $27 → $4
Nov-11-08Reiterated Leerink Swann Outperform $17 → $8
Nov-11-08Reiterated Brean Murray Sell $4 → $2
Nov-11-08Downgrade Piper Jaffray Buy → Sell
Nov-11-08Downgrade Merriman Curhan Ford Buy → Neutral
Oct-16-08Initiated Merriman Curhan Ford Buy
Sep-20-17 04:01PM  Sangamo Therapeutics Announces Presentation At The 2017 Cantor Fitzgerald Global Healthcare Conference PR Newswire
Sep-12-17 06:02AM  The Zacks Analyst Blog Highlights: Caladrius Biosciences, Orexigen Therapeutics, Sangamo Therapeutics and Syndax Pharmaceuticals Zacks
Sep-11-17 01:39PM  Why These 4 Biotech Stocks May Not Lose Momentum Soon Zacks
Sep-05-17 08:10AM  Today's Research Reports on Stocks to Watch: Sangamo Therapuetics and Nutanix ACCESSWIRE
Sep-02-17 10:33AM  3 Biotech Stocks That Skyrocketed This Week Motley Fool
Aug-31-17 04:01PM  Sangamo Presents T Cell Engineering Capabilities at Immuno-Oncology Summit PR Newswire
Aug-30-17 04:01PM  Sangamo Therapeutics Announces Presentations At Upcoming Investor Conferences PR Newswire
Aug-29-17 06:32PM  Why Abeona Therapeutics Inc. (and Maybe Sangamo Therapeutics, Inc.) Jumped Higher Today Motley Fool +11.30%
Aug-28-17 08:09AM  Sangamo Therapeutics Initiates Dosing in Hemophilia A Study Zacks +7.48%
Aug-25-17 08:00AM  Sangamo And Pfizer Announce First Patient Receives Treatment In Phase 1/2 Clinical Trial Evaluating SB-525 Investigational Gene Therapy For Hemophilia A PR Newswire
Aug-20-17 02:02PM  This Stock Could Be the Tesla of Healthcare Motley Fool
Aug-19-17 10:30AM  These Stocks Have Tripled This Year Motley Fool
Aug-16-17 10:25PM  Sangamo Therapeutics, Inc. Value Analysis (NASDAQ:SGMO) : August 17, 2017 Capital Cube -5.36%
Aug-13-17 11:01AM  This Technology Could Make You Rich -- and Change the World As We Know It Motley Fool
10:25AM  Edited Transcript of SGMO earnings conference call or presentation 9-Aug-17 9:00pm GMT Thomson Reuters StreetEvents
Aug-10-17 04:01PM  Sangamo Therapeutics Announces Presentation At The 2017 Wedbush PacGrow Healthcare Conference PR Newswire +12.43%
Aug-09-17 04:31PM  Sangamo reports 2Q loss Associated Press
04:01PM  Sangamo Therapeutics Reports Second Quarter 2017 Financial Results PR Newswire
03:00PM  Investor Network: Sangamo Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-03-17 09:45AM  Sangamo Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SGMO-US : August 3, 2017 Capital Cube
Aug-02-17 04:01PM  Sangamo Therapeutics Announces Second Quarter 2017 Conference Call And Webcast PR Newswire
Jul-17-17 08:50AM  Today's Research Reports on Stocks to Watch: AcelRx Pharmaceuticals and Sangamo Therapeutics Accesswire -6.93%
Jul-13-17 05:56PM  After-hours buzz: CYBR, MYL & more CNBC
04:50PM  Sangamo shares rise as metabolic drugs given FDA fast-track status MarketWatch
04:01PM  Sangamo Receives Fast Track Designation From The FDA For SB-318 And SB-913 In Vivo Genome Editing Product Candidates For The Treatment Of MPS I And MPS II PR Newswire
Jul-07-17 03:29PM  ETFs with exposure to Sangamo Therapeutics, Inc. : July 7, 2017 Capital Cube
Jul-06-17 09:22AM  Despite This Happening, Sangamo Therapeutics Inc. Surged 31% in June Motley Fool
Jun-30-17 08:51AM  Will Sangamo Therapeutics (SGMO) Crush Estimates at Its Next Earnings Report? Zacks
Jun-29-17 04:01PM  Sangamo Therapeutics Appoints Roger Jeffs, Ph.D. and Joseph S. Zakrzewski to its Board of Directors PR Newswire
Jun-26-17 04:05PM  Sangamo Therapeutics Announces Closing Of Public Offering Of Common Stock And Exercise In Full Of Underwriters' Option To Purchase Additional Shares Of Common Stock PR Newswire
Jun-25-17 02:01PM  5 Best Biotech Stocks of 2017 So Far Motley Fool
Jun-22-17 12:33PM  Here's Why Sangamo Therapeutics Rose as Much as 11.7% Today Motley Fool +12.88%
Jun-21-17 08:54AM  3 Stocks to Watch on Wednesday: Carmax, Inc (KMX), Adobe Systems Incorporated (ADBE) and Sangamo Therapeutics Inc (SGMO) InvestorPlace
08:26AM  Sangamo Therapeutics Announces Pricing Of $72.5 Million Public Offering Of Common Stock PR Newswire
Jun-20-17 04:01PM  Sangamo Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire
Jun-07-17 07:30AM  Sangamo Therapeutics And Pfizer Announce That SB-525 Investigational Hemophilia A Gene Therapy Receives Orphan Medicinal Product Designation From The European Medicines Agency PR Newswire
Jun-05-17 02:46PM  ETFs with exposure to Sangamo Therapeutics, Inc. : June 5, 2017 Capital Cube
Jun-02-17 04:01PM  Sangamo Therapeutics Announces Presentation At The Jefferies 2017 Global Healthcare Conference PR Newswire
09:30AM  Universal Display, Hewlett Packard, Regeneron Pharmaceuticals, Sangamo Therapeutics and Puma Biotechnology highlighted as Zacks Bull and Bear of the Day Zacks
May-25-17 12:47PM  ETFs with exposure to Sangamo Therapeutics, Inc. : May 25, 2017 Capital Cube
May-24-17 10:28AM  Sangamo Therapeutics, Inc. :SGMO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017 Capital Cube
May-18-17 05:09AM  Will Sangamo Therapeutics (SGMO) Continue to Surge Higher? Zacks +6.71%
May-17-17 06:14PM  Sangamo's (SGMO) Hemophilia A Drug Gets Fast-Track Status Zacks -6.88%
03:15AM  Edited Transcript of SGMO earnings conference call or presentation 10-May-17 9:00pm GMT Thomson Reuters StreetEvents
May-16-17 07:30AM  Sangamo Receives Fast Track Designation From The FDA For SB-525 Investigational Hemophilia A Gene Therapy PR Newswire
May-15-17 04:01PM  Sangamo Therapeutics Recognizes International MPS Awareness Day And Celebrates The MPS I And MPS II Communities With Stories Of Hope PR Newswire
08:37AM  Is the Options Market Predicting a Spike in Sangamo Therapeutics (SGMO) Stock? Zacks
08:00AM  Sangamo Therapeutics Presents Recent Developments from Research and Clinical Programs at Annual Meeting of the American Society of Gene & Cell Therapy PR Newswire
May-12-17 04:20PM  Why Sangamo Therapeutics Inc. Jumped Higher Today Motley Fool +17.14%
08:00AM  Today's Research Reports on Stocks to Watch: Conatus Pharmaceuticals and Sangamo Therapeutics Accesswire
May-11-17 08:16PM  Edited Transcript of SGMO earnings conference call or presentation 10-May-17 9:00pm GMT Thomson Reuters StreetEvents +60.92%
07:32PM  Sangamo Therapeutics, Inc. Value Analysis (NASDAQ:SGMO) : May 11, 2017 Capital Cube
01:10PM  Here's Why Sangamo Therapeutics Rocketed Up to 56.3% Higher Today Motley Fool
10:30AM  Why Sangamo Therapeutics Is Surging 24/7 Wall St.
May-10-17 05:18PM  Sangamo shares jump on Pfizer collaboration, quarterly results MarketWatch
04:48PM  Sangamo reports 1Q loss Associated Press
04:01PM  Sangamo Therapeutics Reports First Quarter 2017 Financial Results PR Newswire
04:01PM  Sangamo Therapeutics And Pfizer Announce Collaboration For Hemophilia A Gene Therapy PR Newswire
May-09-17 08:51AM  Sangamo Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SGMO-US : May 9, 2017 Capital Cube
May-05-17 08:15AM  Blog Coverage: Sangamo Receives Special Regulatory Designation from FDA for Three of Its Program Accesswire
May-04-17 08:00AM  Sangamo Therapeutics Announces Special Regulatory Designations from the FDA for Three Clinical Programs PR Newswire
May-03-17 04:05PM  Sangamo Therapeutics Announces First Quarter 2017 Conference Call And Webcast PR Newswire
Apr-25-17 04:01PM  Sangamo Announces The Retirement Of Its Founder And Genome Editing Pioneer Edward Lanphier From The Board Of Directors PR Newswire +10.47%
Apr-24-17 05:02PM  Sangamo Therapeutics Announces Presentations at 2017 Annual meeting of the American Society of Gene & Cell Therapy PR Newswire +6.17%
04:03PM  Sangamo Therapeutics Announces Participation In The ARM 5th Annual Cell & Gene Therapy Investor Day PR Newswire
Apr-18-17 08:31AM  Sangamo Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : SGMO-US : April 18, 2017 Capital Cube
Apr-07-17 05:27PM  ETFs with exposure to Sangamo Therapeutics, Inc. : April 7, 2017 Capital Cube
Mar-29-17 07:30AM  Sangamo Therapeutics Announces Presentation of New Data Demonstrating Significant Reduction of Tau Expression Using Proprietary ZFP Gene Regulation Technology PR Newswire +14.81%
Mar-27-17 04:05PM  ETFs with exposure to Sangamo Therapeutics, Inc. : March 27, 2017 Capital Cube
04:05PM  ETFs with exposure to Sangamo Therapeutics, Inc. : March 27, 2017
Mar-21-17 09:26AM  Sangamo Therapeutics, Inc. :SGMO-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017 Capital Cube -6.90%
09:26AM  Sangamo Therapeutics, Inc. :SGMO-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
Mar-20-17 05:08PM  SANGAMO THERAPEUTICS, INC Files SEC form 8-K, Change in Directors or Principal Officers
Mar-14-17 02:30PM  Sangamo Therapeutics, Inc. :SGMO-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017 Capital Cube
02:30PM  Sangamo Therapeutics, Inc. :SGMO-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
Mar-07-17 01:04PM  SANGAMO THERAPEUTICS, INC Financials -8.79%
Mar-01-17 04:05PM  Sangamo Therapeutics Announces Presentation At The Cowen And Company 37th Annual Health Care Conference PR Newswire
08:30AM  Sangamo Therapeutics Receives Orphan Drug Designation from the FDA for SB-913 Genome Editing Treatment for MPS II PR Newswire
Feb-28-17 07:53AM  Sangamo reports 4Q loss Associated Press +5.81%
07:07AM  Q4 2016 Sangamo Therapeutics Inc Earnings Release - Before Market Open
07:03AM  SANGAMO THERAPEUTICS, INC Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or P
07:00AM  Sangamo Therapeutics Reports Fourth Quarter And Full Year 2016 Financial Results PR Newswire
Feb-27-17 04:30PM  Sangamo Therapeutics Announces Chief Financial Officer Succession PR Newswire +7.50%
09:09AM  Biotech Premarket Movers: BioCryst, Sangamo, Cempra
08:00AM  Sangamo Therapeutics Receives Rare Pediatric Disease Designation From FDA For SB-318 In Vivo Genome Editing Therapeutic For MPS I PR Newswire
Feb-24-17 05:11PM  SANGAMO THERAPEUTICS, INC Files SEC form 8-K, Change in Directors or Principal Officers
Feb-21-17 04:03PM  Sangamo Therapeutics Announces Fourth Quarter And Full Year 2016 Conference Call And Webcast PR Newswire
Feb-08-17 04:03PM  Sangamo Therapeutics Announces Upcoming Presentations At The 13th Annual WORLDSymposium Meeting PR Newswire -6.49%
Jan-20-17 01:59PM  ETFs with exposure to Sangamo Therapeutics, Inc. : January 20, 2017 -7.59%
Jan-13-17 09:23AM  Biotech Premarket Movers: SGMO, IPXL, PTLA +11.39%
Jan-11-17 09:08AM  Biotech Premarket Movers: IPXL, SGMO, ARLZ
07:30AM  Sangamo Therapeutics Receives Orphan Drug Designation from the FDA for SB-318 Genome Editing Treatment for MPS I PR Newswire
Jan-10-17 08:00AM  Sangamo Therapeutics Presents Latest Advances In Zinc Finger Nuclease Platform Technology At Keystone Symposium On Precision Genome Engineering PR Newswire
Jan-06-17 08:16AM  SANGAMO BIOSCIENCES INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financia +5.80%
08:00AM  Sangamo BioSciences Changes Name To Sangamo Therapeutics, Underscoring Focus On Clinical Development Of Genomic Therapies PR Newswire
Jan-05-17 08:00AM  Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For SB-525 Gene Therapy Program For Hemophilia A PR Newswire
Jan-04-17 04:05PM  Sangamo BioSciences Announces Presentation At The 35th Annual J.P. Morgan Healthcare Conference PR Newswire +12.90%
Dec-21-16 12:49PM  ETFs with exposure to Sangamo BioSciences, Inc. : December 21, 2016
Dec-12-16 05:44PM  Is Preferred Apartment Communities Inc. (APTS) A Good Stock to Buy? at Insider Monkey
Dec-09-16 02:01PM  ETFs with exposure to Sangamo BioSciences, Inc. : December 9, 2016 +18.52%
Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's proprietary zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off. Its therapeutic products include SB-728-T, a ZFN-mediated autologous T-cell product for human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS), which is in Phase II and Phase I clinical trials; and SB-728-HSPC that is in Phase I/II clinical trials for HIV/AIDS. The company also engages in Phase I/II studies of in vivo genome editing applications of ZFP Therapeutics for hemophilia B, Hemophilia A, and Mucopolysaccharidosis I (MPS) and MPS II, which are lysosomal storage disorder (LSD); proprietary preclinical programs in other LSDs; and research stage programs in certain central nervous system disorders and cancer immunotherapies. It has collaborative partnerships with Biogen Inc. to develop therapeutic genome editing products in hemoglobinopathies; and with Shire International GmbH to develop the preclinical development program in Huntington's disease, as well as license agreement with Sigma-Aldrich Corporation to develop ZFP-based laboratory research reagents and Dow AgroSciences, LLC to modify the genomes or alter protein expression of plant cells, plants, or plant cell cultures. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Richmond, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RINGO WILLIAM RDirectorSep 20Option Exercise6.0531,000187,55031,800Sep 22 04:04 PM
RINGO WILLIAM RDirectorSep 20Sale14.3731,000445,597800Sep 22 04:04 PM
Herberts Curt A. IIISr.VP & Chief Business OfficerSep 01Option Exercise5.4110,31655,81026,149Sep 01 06:19 PM
Herberts Curt A. IIISr.VP & Chief Business OfficerSep 01Sale15.0015,000225,00015,833Sep 01 06:19 PM
Herberts Curt A. IIISr.VP & Chief Business OfficerAug 14Option Exercise5.125,00025,60025,517Aug 15 05:31 PM
Herberts Curt A. IIISr.VP & Chief Business OfficerAug 14Sale11.005,00055,00020,517Aug 15 05:31 PM
Herberts Curt A. IIISr.VP & Chief Business OfficerAug 11Option Exercise3.326,47421,51126,991Aug 15 05:31 PM
Herberts Curt A. IIISr.VP & Chief Business OfficerAug 11Sale10.006,47464,74020,517Aug 15 05:31 PM
Herberts Curt A. IIISr.VP & Chief Business OfficerJul 14Option Exercise3.9917268635,517Jul 14 08:06 PM
Herberts Curt A. IIISr.VP & Chief Business OfficerJul 14Sale10.0015,000150,00020,517Jul 14 08:06 PM
Herberts Curt A. IIISenior VP & CBOJun 01Sale6.802,00013,60035,345Jun 02 08:26 PM
Herberts Curt A. IIISenior VP & CBOMay 12Sale8.502,00017,00037,345May 15 07:42 PM
Herberts Curt A. IIISenior VP & CBOMay 11Sale6.506394,15439,345May 15 07:42 PM